🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 15/04/2002 | 28,14 | 30,93 | 28,02 | 30,82 | +9,48% | 10,34% | 1.387.700 |
| 12/04/2002 | 27,00 | 28,50 | 26,82 | 28,15 | +5,43% | 6,22% | 846.000 |
| 11/04/2002 | 27,32 | 28,19 | 26,66 | 26,70 | -2,02% | 5,60% | 812.400 |
| 10/04/2002 | 26,06 | 27,85 | 26,05 | 27,25 | +5,21% | 6,91% | 768.000 |
| 09/04/2002 | 26,98 | 27,05 | 25,80 | 25,90 | -3,54% | 4,63% | 963.600 |
| 08/04/2002 | 26,10 | 26,99 | 25,70 | 26,85 | +2,52% | 4,94% | 740.500 |
| 05/04/2002 | 26,78 | 27,25 | 25,53 | 26,19 | -1,54% | 6,42% | 612.300 |
| 04/04/2002 | 26,60 | 27,39 | 26,15 | 26,60 | -0,86% | 4,66% | 631.900 |
| 03/04/2002 | 28,65 | 28,65 | 26,09 | 26,83 | -6,35% | 8,94% | 1.111.000 |
| 02/04/2002 | 28,49 | 29,22 | 28,30 | 28,65 | +0,88% | 3,23% | 805.700 |
| 01/04/2002 | 27,79 | 28,91 | 26,85 | 28,40 | +1,94% | 7,41% | 456.300 |
| 28/03/2002 | 27,67 | 28,05 | 27,15 | 27,86 | +1,57% | 3,25% | 638.400 |
| 27/03/2002 | 27,39 | 28,23 | 27,10 | 27,43 | +0,37% | 4,13% | 504.000 |
| 26/03/2002 | 27,74 | 28,48 | 26,76 | 27,33 | -1,34% | 6,20% | 577.300 |
| 25/03/2002 | 28,86 | 29,16 | 27,25 | 27,70 | -3,99% | 6,62% | 384.500 |
| 22/03/2002 | 28,39 | 29,12 | 27,18 | 28,85 | +2,02% | 6,83% | 794.300 |
| 21/03/2002 | 26,76 | 28,50 | 26,13 | 28,28 | +5,80% | 8,86% | 1.497.400 |
| 20/03/2002 | 27,50 | 27,78 | 26,53 | 26,73 | -4,94% | 4,55% | 908.400 |
| 19/03/2002 | 29,50 | 29,60 | 27,19 | 28,12 | -4,58% | 8,17% | 1.607.300 |
| 18/03/2002 | 28,77 | 29,92 | 28,75 | 29,47 | +1,34% | 4,07% | 852.000 |
| 15/03/2002 | 27,44 | 29,25 | 27,22 | 29,08 | +9,08% | 7,40% | 1.710.400 |
| 14/03/2002 | 26,76 | 27,78 | 26,27 | 26,66 | -1,73% | 5,64% | 543.000 |
| 13/03/2002 | 26,01 | 28,37 | 26,00 | 27,13 | +3,91% | 9,11% | 1.174.600 |
| 12/03/2002 | 25,84 | 26,84 | 25,50 | 26,11 | -0,72% | 5,19% | 851.800 |
| 11/03/2002 | 24,30 | 26,87 | 24,25 | 26,30 | +6,05% | 10,78% | 887.500 |
| 08/03/2002 | 24,05 | 24,88 | 24,01 | 24,80 | +3,59% | 3,62% | 724.800 |
| 07/03/2002 | 25,56 | 25,75 | 23,86 | 23,94 | -4,39% | 7,39% | 835.000 |
| 06/03/2002 | 23,05 | 25,04 | 22,88 | 25,04 | +7,93% | 9,37% | 715.100 |
| 05/03/2002 | 22,37 | 23,59 | 22,14 | 23,20 | +3,39% | 6,48% | 584.100 |
| 04/03/2002 | 22,10 | 22,87 | 22,00 | 22,44 | +2,00% | 3,94% | 712.400 |